The recommended dose for adults is 5 microgram tiotropium and 5 microgram olodaterol given as two puffs from the Respimat inhaler once daily at the same time of the day (see Instructions for Use under Cautions for Usage).
Elderly: Elderly patients can use SPIOLTO RESPIMAT at the recommended dose.
Hepatic impairment and renal impairment: SPIOLTO RESPIMAT contains tiotropium which is a predominantly renally excreted drug and olodaterol, which is predominantly metabolized in the liver.
Hepatic impairment: Patients with mild and moderate hepatic impairment can use SPIOLTO RESPIMAT at the recommended dose.
There are no data available for use of olodaterol in patients with severe hepatic impairment.
Renal impairment: Renally impaired patients can use SPIOLTO RESPIMAT at the recommended dose.
SPIOLTO RESPIMAT contains tiotropium, which is a predominantly renally excreted drug. Therefore, SPIOLTO RESPIMAT use should be monitored closely in patients with moderate to severe renal impairment.
Paediatric population: There is no relevant use of SPIOLTO RESPIMAT in the paediatric population in COPD. The safety and effectiveness of SPIOLTO RESPIMAT in the paediatric population have not been established.